• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝移植对两名患有家族性淀粉样多神经病(FAP-met30)的瑞典患者的生化影响。

Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30).

作者信息

Holmgren G, Steen L, Ekstedt J, Groth C G, Ericzon B G, Eriksson S, Andersen O, Karlberg I, Nordén G, Nakazato M

机构信息

Department of Clinical Genetics, University Hospital, Umeå, Sweden.

出版信息

Clin Genet. 1991 Sep;40(3):242-6. doi: 10.1111/j.1399-0004.1991.tb03085.x.

DOI:10.1111/j.1399-0004.1991.tb03085.x
PMID:1685359
Abstract

Familial amyloidotic polyneuropathy (FAP) is an autosomal dominant inherited disorder characterized by progressive peripheral and autonomic neuropathy, associated with neural and systemic amyloid deposits. The amyloid fibrils contain a variant transthyretin (TTR) molecule (TTR met30), over 90% of which is produced in the liver. After liver transplantation in two patients with severe symptomatic FAP, only normal TTR was detectable in circulation. The two patients are being monitored at regular intervals, and, although in one patient there was no evidence of reduction in the quantity of amyloid present at 6 months, there had been no further progression of the neuropathy.

摘要

家族性淀粉样多神经病(FAP)是一种常染色体显性遗传性疾病,其特征为进行性外周和自主神经病变,并伴有神经和全身淀粉样沉积物。淀粉样原纤维含有一种变异的转甲状腺素蛋白(TTR)分子(TTR met30),其中90%以上在肝脏中产生。两名患有严重症状性FAP的患者接受肝移植后,循环中仅可检测到正常的TTR。这两名患者正在接受定期监测,尽管其中一名患者在6个月时没有证据表明存在的淀粉样蛋白数量减少,但神经病变没有进一步进展。

相似文献

1
Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30).肝移植对两名患有家族性淀粉样多神经病(FAP-met30)的瑞典患者的生化影响。
Clin Genet. 1991 Sep;40(3):242-6. doi: 10.1111/j.1399-0004.1991.tb03085.x.
2
Homozygosity for the transthyretin-met30-gene in two Swedish sibs with familial amyloidotic polyneuropathy.两名患有家族性淀粉样多神经病的瑞典同胞中甲状腺素运载蛋白 - met30基因的纯合性。
Clin Genet. 1988 Nov;34(5):333-8. doi: 10.1111/j.1399-0004.1988.tb02887.x.
3
Diagnostic radioimmunoassay and DNA-analysis in Swedish and Japanese patients with familial amyloidotic polyneuropathy. Homozygosity for the TTR met30 gene.瑞典和日本家族性淀粉样多神经病患者的诊断性放射免疫分析及DNA分析。TTR met30基因纯合性。
Acta Neurol Scand. 1993 Feb;87(2):124-7. doi: 10.1111/j.1600-0404.1993.tb04090.x.
4
Diagnostic radioimmunoassay for familial amyloidotic polyneuropathy before clinical onset.临床发病前家族性淀粉样多神经病的诊断性放射免疫分析
J Clin Invest. 1986 May;77(5):1699-703. doi: 10.1172/JCI112489.
5
The first case of familial amyloidotic polyneuropathy (FAP Met30) in the Finnish population.
Hum Hered. 1992;42(3):184-8. doi: 10.1159/000154064.
6
Homozygosity for the transthyretin-Met30-gene in seven individuals with familial amyloidosis with polyneuropathy detected by restriction enzyme analysis of amplified genomic DNA sequences.
Clin Genet. 1992 Jan;41(1):39-41. doi: 10.1111/j.1399-0004.1992.tb03627.x.
7
Biochemical marker in familial amyloidotic polyneuropathy, Portuguese type. Family studies on the transthyretin (prealbumin)-methionine-30 variant.葡萄牙型家族性淀粉样多神经病的生化标志物。转甲状腺素蛋白(前白蛋白)-蛋氨酸-30变异体的家族研究。
J Clin Invest. 1985 Dec;76(6):2171-7. doi: 10.1172/JCI112224.
8
Amyloidotic polyneuropathy in a Jewish family. Evidence for the genetic heterogeneity of the lower limb familial amyloidotic neuropathies.一个犹太家庭中的淀粉样变性多发性神经病。下肢家族性淀粉样变性神经病遗传异质性的证据。
Q J Med. 1985 Apr;55(216):33-44.
9
[Treatment of familial amyloid polyneuropathy].[家族性淀粉样多神经病的治疗]
Presse Med. 2012 Sep;41(9 Pt 1):793-806. doi: 10.1016/j.lpm.2011.11.027. Epub 2012 Feb 16.
10
Presence of a plasma transthyretin (prealbumin) variant in familial amyloidotic polyneuropathy in a kindred of Greek origin.在一个希腊裔家族的家族性淀粉样多神经病中存在血浆转甲状腺素蛋白(前白蛋白)变体。
J Lab Clin Med. 1986 Jul;108(1):17-22.

引用本文的文献

1
Transthyretin Kinetic Stabilizers for ATTR Amyloidosis: A Narrative Review of Mechanisms and Therapeutic Benefits.用于转甲状腺素蛋白淀粉样变性的转甲状腺素蛋白动力学稳定剂:作用机制与治疗益处的叙述性综述
Cardiol Ther. 2025 Sep;14(3):333-350. doi: 10.1007/s40119-025-00423-7. Epub 2025 Jul 29.
2
Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review.评估帕替西兰和维曲西兰在治疗伴有多发性神经病的转甲状腺素蛋白淀粉样变中的有效性和安全性:一项系统评价。
Front Neurol. 2024 Sep 2;15:1465747. doi: 10.3389/fneur.2024.1465747. eCollection 2024.
3
Ocular findings in patients with acquired ATTRv amyloidosis following domino liver transplantation.
接受多米诺式肝移植后获得性ATTRv 淀粉样变性患者的眼部表现。
PLoS One. 2023 Sep 15;18(9):e0291716. doi: 10.1371/journal.pone.0291716. eCollection 2023.
4
Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation.肝移植后伴多发性神经病的遗传性ATTR 淀粉样变性患者中 patisiran 的药代动力学和药效学。
Clin Pharmacokinet. 2023 Oct;62(10):1509-1522. doi: 10.1007/s40262-023-01292-w. Epub 2023 Aug 28.
5
Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.伏硫西汀对遗传性转甲状腺素蛋白介导的淀粉样变多发性神经病患者生活质量和身体功能的影响。
Neurol Ther. 2023 Oct;12(5):1759-1775. doi: 10.1007/s40120-023-00522-4. Epub 2023 Jul 31.
6
Status and Future Directions of Therapeutics and Prognosis of Cardiac Amyloidosis.心脏淀粉样变性的治疗现状与未来方向及预后
Ther Clin Risk Manag. 2023 Jul 10;19:581-597. doi: 10.2147/TCRM.S414821. eCollection 2023.
7
RNA interference in late-stage hereditary transthyretin amyloidosis: a clinicopathological study.晚期遗传性转甲状腺素蛋白淀粉样变性中的RNA干扰:一项临床病理研究
J Neurol. 2023 Sep;270(9):4544-4548. doi: 10.1007/s00415-023-11754-7. Epub 2023 May 8.
8
Brazilian consensus for diagnosis, management and treatment of hereditary transthyretin amyloidosis with peripheral neuropathy: second edition.巴西遗传性转甲状腺素蛋白淀粉样变性伴周围神经病的诊断、治疗和管理共识:第二版。
Arq Neuropsiquiatr. 2023 Mar;81(3):308-321. doi: 10.1055/s-0043-1764412. Epub 2023 Apr 14.
9
Tafamidis concentration required for transthyretin stabilisation in cerebrospinal fluid.转甲状腺素蛋白稳定剂在脑脊液中的浓度。
Amyloid. 2023 Sep;30(3):279-289. doi: 10.1080/13506129.2023.2167595. Epub 2023 Jan 24.
10
The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates.N-乙酰半乳糖胺-siRNA 偶联物的治疗前景。
Front Pharmacol. 2022 Dec 14;13:1090237. doi: 10.3389/fphar.2022.1090237. eCollection 2022.